Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company engaged in developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s R&D activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. The company has global rights to a portfolio of five therapeutic programs in clinical trials or … Continue reading “Viking Therapeutics, Inc. (NASDAQ: VKTX) Starts Presentation at 30th Annual ROTH Conference”
Ritter Pharmaceuticals (NASDAQ: RTTR) is engaged in the development of novel therapeutics that modulate the gut microbiome to treat gastrointestinal diseases. RP-G28, the company’s lead product, has the potential to become the very first FDA-approved lactose intolerance treatment, addressing a condition that affects millions of individuals throughout the world. This product has been studied in … Continue reading “Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Starts Presentation at 30th Annual ROTH Conference”
Panhandle Oil and Gas (NYSE: PHX) is engaged in the exploration for and production of natural gas and oil. The majority of Panhandle Oil and Gas Inc.’s revenues are derived from the production and sale of oil and natural gas. The company’s oil and gas holdings, including its 255,000 net mineral acreage and its working … Continue reading “Panhandle Oil and Gas, Inc. (NYSE: PHX) Starts Presentation at 30th Annual ROTH Conference”
SenesTech (NASDAQ: SNES) is engaged in developing proprietary technologies to manage animal pest populations through fertility control. The company’s focus is on changing the paradigm of pest management by targeting the root problem of reproduction—an approach that can potentially help reduce reliance on lethal methods of rodent control. The company’s ContraPest® is a pioneering technology … Continue reading “SenesTech, Inc. (NASDAQ: SNES) Starts Presentation at 30th Annual ROTH Conference”
Advanced medical software company ORHub, Inc. (OTC: ORHB) this morning announced its appointment of Ray Oliver as its new senior vice president of operations. In this position, Oliver will be responsible for the expansion of customer success, implementation, sales and support organizations. “Ray is joining ORHub at a critical time when we are expanding and … Continue reading “NetworkNewsBreaks – ORHub, Inc. (ORHB) Appoints Senior Vice President of Operations”
Hemispherx Biopharma (NYSE: HEB) is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod. Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the … Continue reading “Hemispherx Biopharma, Inc. (NYSE: HEB) Starts Presentation at 30th Annual ROTH Conference”
ArQule (NASDAQ: ARQL) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. The company’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need to significantly extend and improve the lives of patients. The company’s clinical-stage pipeline consists … Continue reading “ArQule, Inc. (NASDAQ: ARQL) Starts Presentation at 30th Annual ROTH Conference”
Mattersight (NASDAQ: MATR) provides behavioral analytics services in the United States. The company provides predictive behavioral routing, performance management, quality assurance, predictive analytics, and marketing managed services that analyzes and predicts customer behavior based on the language exchanged between agents and customers during brand interactions to enhance customer satisfaction and retention, employee engagement, and operating … Continue reading “Mattersight Corp. (NASDAQ: MATR) Starts Presentation at 30th Annual ROTH Conference”
Stemline Therapeutics (NASDAQ: STML) is a clinical-stage biopharmaceutical company engaged in the development of novel oncology therapeutics. The company is currently developing three clinical-stage product candidates: SL-401, SL-801 and SL-701. Stemline’s preclinical pipeline includes two next-generation IL-3R-targeted compounds: SL-501 and SL-101. The company has additionally constructed an innovative drug discovery platform called StemScreen™ and has … Continue reading “Stemline Therapeutics, Inc. (NASDAQ: STML) Starts Presentation at 30th Annual ROTH Conference”
Contango Oil & Gas Company (NYSE: MCF) is a Houston, Texas-based, independent energy company engaged in the acquisition, exploration, development, exploitation and production of crude oil and natural gas offshore in the shallow waters of the Gulf of Mexico and in the onshore Texas and Rocky Mountain regions of the United States. For more information, … Continue reading “Contango Oil & Gas Company (NYSE: MCF) Starts Presentation at 30th Annual ROTH Conference”
